VA
APLT

VR Adviser’s Applied Therapeutics APLT Stock Holding History

VR Adviser’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,567,709
Closed -$2.72M – 32
2025
Q1 		$2.72M Sell
5,567,709
-4,422,882
-44% -$2.6M 0.23% 29
2024
Q4 		$8.55M Buy
9,990,591
+165,591
+2% +$1.04M 0.59% 26
2024
Q3 		$83.5M Buy
9,825,000
+282,129
+3% +$1.66M 4.37% 5
2024
Q2 		$44.6M Buy
9,542,871
+467,871
+5% +$2.21M 2.84% 13
2024
Q1 		$61.7M Buy
9,075,000
+2,825,000
+45% +$12.7M 2.94% 12
2023
Q4 		$20.9M Buy
6,250,000
+591,966
+10% +$1.47M 1.44% 23
2023
Q3 		$14.1M Hold
5,658,034
– – 1.48% 22
2023
Q2 		$7.24M Buy
+5,658,034
New +$7.51M 1.16% 19

Other funds holding APLT

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

VR Adviser's APLT Position: Q2 2025 in Review

VR Adviser sold out of Applied Therapeutics (APLT) in Q2 2025, closing a stake of 5,567,709 shares — an estimated $2.72M sold.

VR Adviser first reported a position in APLT in Q2 2023 and held it in 8 quarters. The position peaked at $83.5M in Q3 2024. 75 funds tracked by Wall St. Rank hold APLT as of Q2 2025.

  • VR Adviser reported no remaining Applied Therapeutics position as of Q2 2025 after selling out during the quarter.
  • VR Adviser sold 5,567,709 Applied Therapeutics shares in Q2 2025, an estimated $2.72M.
  • VR Adviser first reported a position in Applied Therapeutics in Q2 2023 and held it in 8 quarters.
  • VR Adviser's Applied Therapeutics position peaked at $83.5M in Q3 2024.
  • 75 funds tracked by Wall St. Rank held Applied Therapeutics as of Q2 2025.

Based on VR Adviser's 13F filing for Q2 2025, filed 14 Aug 2025.